Exchange: NASDAQ·Updated 05:37 PM EDT
News
all
press releases
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
STERIS beats fiscal Q1 earnings estimates as sales rise 7.3%, but a modest revenue miss sends shares 2.4% lower after hours.
Zacks
More News
Is MEDP Worth Buying as Growth Collides With a Premium Valuation?
Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.
Zacks
ZBH's Q2 Earnings Beat, '26 View Raised, Stock Up in Pre-Market
ZBH beats second-quarter earnings and revenue estimates, raises its 2026 outlook and gains in pre-market despite pressure on adjusted margins.
Zacks
CRL Q2 Earnings and Revenues Top, '26 View Up, Stock Up in Pre-Market
Charles River beats Q2 earnings and revenue estimates, raises 2026 outlook and gains 7.9% in pre-market trading.
Zacks
Can MEDP's Record Q2 Bookings Build a Stronger Growth Path for 2027?
Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?
Zacks
CVS Health Q2 Earnings and Revenues Top Estimates, Stock Climbs
CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.
Zacks
Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?
IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.
Zacks
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Zacks
HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs
Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.
Zacks
Why Medpace (MEDP) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks

Advertisement|Remove ads.